Ravindra Majeti MD

PubMed

• 1 citations
  Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement.
  Uma Borate, Kelly Pugh, Allyson Waller, Rina Li Welkie, Ying Huang
  Blood. 2025-03-27
• A CEBPB/IL-1β/TNF-α Feedback Loop Drives Drug Resistance to Venetoclax and MDM2 Inhibitors in Monocytic Leukemia.
  Basil Allen, Daniel Bottomly, Thomas Köhnke, Anthony Wang, Hsin-Yun Lin
  Blood. 2025-02-26
• The improved prognosis of-internal tandem duplication but not tyrosine kinase domain mutations in acute myeloid leukemia in the era of targeted therapy: a real-world s...
  Matthew Schwede, Gladys Rodriguez, Vanessa E Kennedy, Solomon Henry, Douglas Wood
  Haematologica. 2025-02-06

Journal Articles

• Macrophage De Novo NAD+ Synthesis Specifies Immune Function in Aging and Inflammation  
  Ravindra Majeti, Paras S Minhas, Katrin I Andreasson, Christopher Dove, Nature
• CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma  
  Mark P Chao, Sonali M Smith, Ranjana Advani, Ian Flinn, Ravindra Majeti, Nancy L Bartlett, Leslie Popplewell, Justin Kline, Nilanjan Ghosh, Ann LaCasce, The New England Journal of Medicine

Abstracts/Posters

• Enasidenib Drives Maturation of Human Erythroid Precursors Independently of IDH2
  Ravindra Majeti, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Reprogramming Leukemia Cells into Antigen Presenting Cells As a Novel Cancer Vaccination Immunotherapy
  Ravindra Majeti, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/2019

Lectures

• Metabolism and Hematologic Malignancies 
  60th American Society of Hematology Annual Meeting - 12/2/2018
• Single-Cell Mutational Profiling of Clonal Evolution in De Novo AML during Therapy and Relapse 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018